Siagran Contraindications

1. Hypersensitivity to Sumatriptan or any component of the formulation.
2. Because Sumatriptan has the potential to cause vasospasm, it is contraindicated in patients who have ischemic heart disease or signs or symptoms of ischemic heart disease; including Prinzmetal's angina, angina pectoris, myocardial infarction, silent myocardial ischemia, coronary artery vasospasm and peripheral vascular disease; including ischemic bowel disease.
3. Sumatriptan is contraindicated in patients who have cerebrovascular syndromes; including strokes, transient ischemic attacks.
4. Sumatriptan is contraindicated in patients with uncontrolled hypertension.
5. Sumatriptan is contraindicated in patients with Wolff-Parkinson-White syndrome (symptoms: palpitations, dizziness, lightheadedness, fainting) or arrhythmias associated with other cardiac accessory conduction pathway disorders.
6. Sumatriptan is contraindicated in patients with hemiplegic or basilar migraine.
7. Sumatriptan also is contraindicated in patients with severe hepatic impairment.
8. Concomitant use of Sumatriptan and monoamine oxidase inhibitors (MAOIs) especially, isoenzyme A (MAO-A inhibitors: e.g. moclobemide) therapy or within 2 weeks of discontinuing MAOIs is contraindicated because these drug can increase systemic exposure to Sumatriptan. 9. The use of Sumatriptan within 24 hours of treatment with ergot alkaloids.
10. Coadministration of two 5-HT₁ agonist within 24 hours of each other is contraindicated.